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ABSTRACT The regulation of latency is central to herpesvirus biology. Recent
transcriptome-wide surveys have uncovered evidence for promiscuous transcription
across the entirety of the Kaposi’s sarcoma-associated herpesvirus (KSHV) genome
and postulated the existence of multiple viral long noncoding RNAs (lncRNAs). Next-
generation sequencing studies are highly dependent on the specific experimental
approach and particular algorithms of analysis and therefore benefit from indepen-
dent confirmation of the results. The antisense-to-latency transcript (ALT) lncRNA
was discovered by genome-tiling microarray (Chandriani et al., J Virol 86:7934–7942,
2010, https://doi.org/10.1128/JVI.00645-10). To characterize ALT in detail, we physi-
cally isolated this lncRNA by a strand-specific hybrid capture assay and then em-
ployed transcriptome sequencing and novel reverse transcription-PCR (RT-PCR) as-
says to distinguish all RNA species in the KSHV latency region. These methods
confirm that ALT initiates at positions 120739/121012 and encodes a single splice
site, which is shared with the 3=-coterminal K14-vGPCR/ORF74 mRNA, terminating at
130873 (GenBank accession number GQ994935), resulting in an 10,000-nucleotide
transcript. No shorter ALT isoforms were identified. This study also identified a novel
intron within the LANA 5= untranslated region using a splice acceptor at 127888. In
summary, ALT joins PAN/nut1/T1.1 as a bona fide lncRNA of KSHV with potentially
important roles in viral gene regulation and pathogenesis.
IMPORTANCE Increasing data support the importance of noncoding RNAs (ncRNAs),
including microRNAs (miRNAs) and lncRNAs, which have been shown to exert critical
regulatory functions without coding for recognizable proteins. Defining the sequences
of these ncRNAs is essential for future studies aiming to functionally characterize a spe-
cific ncRNA. Most lncRNA studies are highly dependent on high-throughput sequenc-
ing and bioinformatic analyses, few studies follow up on the initial predictions, and
analyses are at times discordant. The manuscript characterizes one key viral lncRNA,
ALT, by physically isolating ALT and by a sequencing-independent assay. It provides
for a simple assay to monitor lncRNA expression in experimental and clinical sam-
ples. ALT is expressed antisense to the major viral latency transcripts encoding LANA
as well as the viral miRNAs and thus has the potential to regulate this key part of
the viral life cycle.
KEYWORDS long noncoding RNA, lncRNA, Kaposi’s sarcoma-associated herpesvirus,
KSHV, antisense-to-latency transcripts, ALT, LANA, gene expression, RNA enrichment,
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Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 causesKaposi’s sarcoma (KS), a cancer of endothelial cells that is a signature of the
worldwide AIDS epidemic. In addition, KSHV instigates primary effusion lymphoma
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(PEL) and the plasmablastic variant of multicentric Castleman disease (MCD). These are
rare but aggressive proliferative diseases of B cells that carry a poor prognosis even
with treatment (1–3). There are no vaccines against KSHV. Standard therapies for KS,
PEL, and MCD rely on cytotoxic therapy and improvement of immune system function
in the context of HIV or organ transplantation. KSHV persists and replicates in the
nucleus of infected cells, where its 165- to 170-kb double-stranded DNA (dsDNA)
genome (4) is associated with histones and organized into transcriptionally active and
inactive gene blocks, as inferred by different types of chromatin modifiers (5–10). Like
other herpesviruses, KSHV undergoes a latent stage of its life cycle during which no viral
progeny are produced, but the virus can reactivate and enter lytic replication. During
latency, KSHV transcription is limited (11, 12), but reactivation to lytic replication
initiates a cascade of RNA polymerase II-dependent transcription that spans the entire
genome (13, 14).
Long noncoding RNAs (lncRNAs) belong to a diverse subclass of RNA molecules that
lack obvious protein-coding potential and are classified by their relatively large size
(200 nucleotides [nt]) compared to smaller RNAs, such as microRNAs (miRNAs).
Increasing evidence suggests that lncRNAs play key roles in cell differentiation, patho-
genesis of cancer and other diseases, regulation of gene expression, and interactions
between virus and host during infection (15–17). By virtue of their large size and
numerous secondary and tertiary interactions, lncRNAs can form complex structures
and serve as molecular scaffolds for protein complexes. In addition, single-stranded
regions of lncRNAs can base pair with cDNA or RNA, allowing for silencing of specific
mRNAs or for targeting of protein complexes to specific genomic loci. A notion that has
gained prominence recently is that some lncRNAs can serve as sponges for miRNAs
(15–17). More than two dozen human lncRNAs have been associated with human
cancers, as the expression of these lncRNAs in tumors is dysregulated in a manner
similar to that seen with protein-coding genes and miRNAs (16, 17). In addition, the
expression of certain lncRNAs has been correlated with the degree of cancer prognosis
and shown to play a role in metastasis, invasiveness, cell proliferation, and regulation
of tumor suppressor proteins (16–18).
Like the human cells it infects, KSHV encodes a number of lncRNAs (13, 19–24). One
of these viral lncRNA transcripts, polyadenylated nuclear (PAN) RNA, has been known
for 2 decades (22, 25). Its origin and regulation has been well characterized (22, 25–32).
In situ studies showed that PAN RNA is either not expressed or expressed at low basal
levels during latency (33, 34) and then is induced to higher levels during lytic reacti-
vation; however, PAN RNA is either the most abundant or among the most abundant
transcripts during de novo infection (35, 36). PAN RNA has been reported to inhibit the
expression of immune response genes such as interleukin-4 and gamma interferon, to
interact with several viral and cellular proteins, to act as a global regulator of viral genes
by interacting with cellular transcriptional regulators and chromatin-modifying pro-
teins, and to potentially encode small peptides from noncanonical open reading frames
(ORFs) (13, 26–29, 37–39). Although PAN RNA is one of the best-studied lncRNAs in
KSHV, its complete repertoire of interactions and functions is still not fully understood
(40). In addition to PAN RNA, some functional insights have been reported for three
other KSHV lncRNAs: T3.0, T1.2, and T1.5 (the numbers indicate the transcript length in
kilobase pairs). T3.0 and T1.2, which share a transcription start site (TSS) and are
antisense to the mRNA of RTA (replication and transcription activator; ORF50), do not
inhibit RTA (41). T1.5, a transcript near one of the two origins of lytic replication (ori-Lyt),
is an immediate-early gene, and its transcription is required for viral replication (24, 42).
Although these three lncRNAs do not have canonical ORFs, all have been reported to
be ribosome associated (13, 41). In support of the potential to produce small peptides
(100 amino acids), a portion of T1.5 is found in the cytoplasm by Northern blotting
and by RNA fluorescence in situ hybridization (FISH) (21), whereas T3.0 produces at least
three small peptides (41), one of which induces its antisense transcript RTA (43). PAN
RNA and T1.5 are also packaged within virions and expressed in the early stages of
primary infection, suggesting an important role in establishing a successful infection
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(35, 36). Two other lncRNAs, ALT (antisense-to-latency transcripts) and T6.1, have been
consistently observed in transcriptome sequencing (RNA-seq) surveys. Evidence for
additional, less prominent viral lncRNAs can also be found as a by-product of mRNA
transcriptome mapping studies (13, 19–21, 23, 44). The exact origin and regulation of
many of these potential lncRNAs are not well defined at this time.
There is evidence of permissive transcription surrounding and across the ori-Lyt loci
in KSHV, including lncRNAs T1.5, T6.1, and ALT, the microRNA cluster, and several
protein-coding transcripts (13, 19, 23, 24, 45, 46). This feature is analogous to other DNA
viruses, where transcription is sometimes seen as a means to keep ori-Lyt from
becoming engulfed in repressive chromatin. In the case of Epstein-Barr virus (EBV),
latent transcripts LMP2A and LMP2B cross the terminal repeat regions (47), which are
fused and serve as the origin of replication for the circular plasmid during latency.
Similar evidence for KSHV transcripts traversing the latent origin of replication, which,
like in EBV, is comprised of fused terminal repeats, is missing due to the difficulty of
mapping transcripts across these regions, although the mRNAs for the orthologous
KSHV latent membrane proteins K1 and K15 originate proximal to the latent origin
(48–51).
Of the more than a dozen potential lncRNAs in the KSHV genome that have been
proposed on the basis of transcriptome-wide studies, most were detected in lytically
reactivated cells. Many are not consistently detected across independent studies, and
their transcriptional start and termination sites remain ill-defined. Unlike lncRNA PAN,
the more recently reported and less abundant KSHV lncRNAs tend to run opposite of
known coding regions and are thus antisense to known lytic mRNAs. The detailed
functional characterization of these novel lncRNAs is dependent upon first creating a
detailed map of their boundaries. We sought to address this gap in our understanding
of KSHV by studying the transcription of one new KSHV lncRNA in detail and confirm
its expression by means other than next-generation (NextGen) sequencing. We selected
the KSHV lncRNA ALT (19), which lies opposite the well-characterized KSHV latency
locus transcripts.
RESULTS
An updated map of known and potential KSHV mRNAs, miRNAs, and
lncRNAs. Arias et al. published KSHV 2.0, which mapped poly(A)-containing viral RNAs
and assessed their translational status using ribosomal profiling (13), while Dresang et
al. combined a tiling microarray with liquid chromatography and tandem mass spec-
trometry to explore the protein-coding capacity of the transcriptome (20). A high-
throughput transcriptional mapping approach was taken by Majerciak et al. (21),
whereas Chandriani et al. focused on tiling microarray supported by Northern blotting
or 3= rapid amplification of cDNA ends (RACE) (19). From these studies at least 16
potential lncRNAs have been reported (13, 19–21), although there are discrepancies
between the different approaches (Table 1). Seven potential lncRNAs found by tiling
microarray (19, 20) were not detected by subsequent RNA-seq studies (13, 21, 59, 60).
We sought to integrate these and prior studies (1, 13, 19–21, 50, 59–61) into an
updated, comprehensive map of KSHV transcription annotations (Fig. 1).
At a global level, our analysis of existing data sets found evidence of extensive
overlapping and antisense transcription across the entire KSHV genome which was
not previously appreciated, as very few of the initially defined open reading frames
(ORFs) overlap in KSHV. Nearly the entire genome is transcribed during lytic replication.
Several of the KSHV lncRNAs overlap not only mRNAs but also each other, either on the
same strand or on opposite strands. For instance, lncRNAs T1.5 and PAN RNA com-
pletely overlap T6.1 on the same strand, while PAN RNA is antisense to the anti-PAN
lncRNA (Fig. 1). A large number of KSHV lncRNAs are reported to have ill-defined
boundaries due to limitations in the methods used for their initial discovery. lncRNAs
whose 5= and/or 3= ends have not yet been determined were classified as ill-defined
in Table 1 and colored gray in Fig. 1, while lncRNAs with well-defined boundaries
across multiple independent studies were annotated as such (Table 1; colored purple
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in Fig. 1). Two lncRNAs, as-vIL6-K4.2 and as-K9-ORF62, were annotated solely based on
a verbal description in the results section of a single report (13), while three others,
as-ORF65-69, as-vGPCR, and as-ORF75, were mapped by estimating their coordinates
based on a published figure (19).
KSHV lncRNA ALT is an early lytic transcript. ALT is too large and not sufficiently
abundant to be reliably assessed by Northern blotting. Conventional reverse
transcription-PCR (RT-PCR) methods of detecting RNA are difficult for the ALT lncRNA
due to the highly abundant latency transcripts in an overlapping region on the
opposite strand (see Fig. 3). To improve sensitivity and specificity, we designed pools
of biotinylated antisense oligonucleotides (ASOs) to capture strand-specific RNA by
using streptavidin-coupled magnetic beads (62, 63). To assess this enrichment, we used
RT-PCR of control RNAs and regions unique to ALT. This strategy is applicable to
lncRNAs whose ends are not well known, since capture oligonucleotides can be
designed antisense to any region with evidence of transcription.
To validate this approach, we used the well-characterized human lncRNA MALAT1
(metastasis-associated in lung adenocarcinoma transcript 1; also called NEAT2, for
nuclear-enriched abundant transcript 2). First, we tested our ability to reverse transcribe
full-length MALAT1, as lncRNAs are often difficult templates to extend due to their
extensive length and secondary structure. We isolated total RNA from 2 million cells of
the PEL cell line TREx BCBL1-RTA (64). Using oligo(dT) to initiate reverse transcription,
we verified that three commercial reverse transcriptase (RT) enzymes could generate
the full 6.6 kb of MALAT1 cDNA from its 3=-poly(A) tail to its 5= end (as ascertained by
primer MALAT#1). Importantly, of the three we tested, only ThermoScript RT also
avoided false priming (65), which is critical to this study, as false priming obscures the
strand origin for cDNA sequences and can lead to artifacts in stranded RNA-seq
approaches. All oligonucleotide primer pairs for RT-PCR experiments amplified the
appropriately sized products from genomic DNA (see Fig. 4B).
TABLE 1 Potential lncRNAs in KSHV
Descriptive name and
categorya Alias(es)a
Genome coordinatesb
Direction Size (kb)
Genome-wide screenc
Start End A B C D
Undefined end(s)
as-K1/ORF4-11 ALE; K1.3; K1/11-AS 17000 21 L 17.0   
as-vIL6/ORF2 K1.5 17200 18215 R 1.0  
as-vIL6/K4.2 K2/K4.2-AS 17200 23000 R 5.8 
as-K4s K3.5 22100 22979 R 0.9 
as-PAN/K7 K7.3; anti-PAN 29700 28413 L 1.3 
as-K9/ORF62 83700 101000 R 17.3 
as-ORF58/59 K11.5 94300 96779 R 2.5 
as-ORF65/69 111000 118500 R 7.5 
as-vGPCR 133000 129000 L 4.0 
as-ORF7 133300 134100 R 0.8 
Defined ends
as-K5/K6 K4.5; T6.1; K5/6-AS 23542 29690 R 6.1f   
as-IR K4.7; T1.5 24191 25394 R 1.2f   
PAN RNAd nut1; T1.1 28611 29690 R 1.1   
as-RTA K7.7; T3.0; 50AS-L 74334 71423 L 2.9  
as-RTAe T1.2; 50AS-S 74334 73302 L 1.0
as-miR/K13/72/LANA ALT; K12.5 120739;121012 130871 R 10.1f; 9.9f    
aUnderlined names are those used in this study. One or more ends of undefined lncRNAs have not been determined. Abbreviations: as, antisense; vIL6, viral homolog
to interleukin-6 (ORF K2); vGPCR, viral G protein-coupled receptor (ORF74); IR, internal repeats; PAN RNA, polyadenylated nuclear RNA; RTA, replication and
transcription activator (ORF50); miR, microRNAs; LANA, latency-associated nuclear antigen (ORF73); ALE, antisense to left end; anti-PAN, antisense to PAN RNA; nut1,
nuclear U-RNA-like transcript 1; ALT, antisense to latency transcripts.
bCoordinates from each reference were extrapolated to the KSHV strain JSC1 genome (GQ994935.1).
cReferences for genome-wide screens are the following: A, Arias et al. (13), RNA-seq and ribosomal profiling; B, Chandriani et al. (19), tiling microarray; C, Dresang et
al. (20), tiling microarray; D, Majerciak et al. (21), RNA-seq.
dReferences for PAN/nut1/T1.1 RNA are the following: 12, 22, 25–40, and 52–58.
eReported in reference 41.
fActual size may vary due to differences in length of interior repetitive regions.
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FIG 1 Updated map of known and potential KSHV mRNAs, miRNAs, and lncRNAs. Coordinates of RNA transcripts
from the literature were extrapolated to the KSHV strain JSC1 genome (GQ994935.1) and visualized with CLC Bio’s
Genomics Workbench software. The boundaries of ill-defined lncRNAs have not been determined, and their
existence has not been validated. See the .gff file at https://www.med.unc.edu/orfeome/downloads/annotated-
target-genomes for a more detailed annotation, including CDS, TSS, pA signals, TTS, repeats, and origins of
replication.
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For strand-specific enrichment of MALAT1, we designed a pool of ASOs comple-
mentary to the 3= end of MALAT1 transcripts starting near the transcription termination
sequence (TTS) and spaced roughly every 200 nucleotides (Fig. 2A, dotted black lines,
with numbering as shown in Table 2). Total RNA was incubated with the MALAT1-
specific pool of biotinylated ASOs, and then ASO-bound RNA was isolated on
streptavidin-coupled magnetic beads. RNA-ASO-bead complexes were washed on a
magnetic stand to remove nonspecific interactors, and then the RNA of interest was
eluted from ASO-bead complexes by high-temperature incubation. To assess the
enrichment of MALAT1 transcripts, we performed RT-PCR on input or captured RNA
using three MALAT1 amplicons (Fig. 2A, gray shading) and a negative-control amplicon
for the highly abundant GAPDH mRNA. All RNA was incubated with or without RT, and
no amplification was observed in the non-RT control samples (Fig. 2B). The RT-PCR
products were visualized by a Caliper LabChip GX microfluidic instrument, which allows
for high-accuracy sizing and quantification. All three MALAT1 regions were amplified
from captured RNA at levels similar to input RNA, while GAPDH mRNA was significantly
reduced in the captured RNA compared to the input (Fig. 2B). Here and in subsequent
experiments, we added random hexamers to the RT reaction to increase consistency
across captured lncRNAs of unknown size (Fig. 2B). These results establish that target
RNAs, up to an estimated length of 6,600 nucleotides (nt), can be selectively enriched
and converted to full-length cDNA using this method.
As the name suggests, ALT lies on the opposite strand of the latency (Lat) transcripts
(11, 30, 66), completely overlapping most of them (Fig. 3). In addition, ALT is on the
same strand and is coterminal with a bicistronic lytic transcript containing ORF K14
(v-OX2, a homolog of cellular surface receptor OX2) and ORF74 (vGPCR, for viral G
protein-coupled receptor) (19, 67). With such extensive overlapping transcription,
careful placement of oligonucleotide primers is paramount when trying to detect,
capture, and distinguish individual transcript isoforms in this region. To distinguish
FIG 2 Enrichment of human lncRNAMALAT1. (A) Biotinylated antisense oligonucleotides (ASOs; positions
marked by dotted lines and numbered as shown in Table 2) and streptavidin-coupled magnetic beads
were used to enrich the two major isoforms of lncRNA MALAT1 from TREx BCBL1-RTA cells at 12 h
postlytic reactivation. Three amplicons (shaded gray) were used to assess the enrichment of RNA by
RT-PCR. The polyadenylation (pA) signal for the minor isoform is marked by a gray vertical line, and the
genome-encoded poly(A) tract for the major isoform (86) is marked by a black line. (B) MALAT1 was
enriched as detected by all three amplicons (amp), while negative-control RNA GAPDH was not. All
samples were run with or without RT. inp, RNA input; cap, ASO-captured RNA.
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between the ALT lncRNA and the KSHV latency locus mRNAs, we used primers that
span or lie within introns of the latency locus mRNAs and only permit amplification of
transcripts from one strand or another (Fig. 3, blue shading). Two such strand-specific
primer pairs (ALT specific or LT2, as listed in Table 2) were designed to only generate
a single amplified product from one of the two opposing strands. The first, the
ALT-specific primer pair (Fig. 3), lies completely within the introns of various latent
LANA (latency-associated nuclear antigen) transcripts or upstream of a lytic transcript,
labeled LANA LytT, on the bottom strand. It is also upstream of the K14-ORF74
bicistronic transcript on the top strand. Therefore, the ALT-specific primer pair only
amplifies ALT cDNA. The second primer pair, the LT2 primer pair, has the potential to
TABLE 2 Primers used for RT-PCR assessment and enrichment of transcripts
Name and category Sequencea
RT-PCR of human transcripts
MALAT1-Amp1-F204 5=-GAGAAAGGACTACAGAGCCCCG
MALAT1-Amp1-R204 5=-AAATGACGCAATTCTCCCTGCG
MALAT1-Amp2-F200 5=-CCATTGGGGAATAAGCATAACCCTG
MALAT1-Amp2-R200 5=-TGAGATGGACATTGCCTCTTCATTG
MALAT1-Amp3-F190 5=-TTCATTTCTGGTGGTGGGAGGG
MALAT1-Amp3-R190 5=-CCAAGGGAGGGGAGAGAGAAAC
GAPDH-F 5=-ATGACATCAAGAAGGTGGTGAA
GAPDH-R 5=-GCTGTTGAAGTCAGAGGAGAC
RT-PCR of KSHV transcripts
ORF72-F 5=-CCAGTTCACTTTGCTATGCCG
ORF72-R 5=-GTGACGTCCGTCGCTAAGAC
ALT-specific-F 5=-TAATCCGGGCGTGAGAAACA
ALT-specific-R 5=-CCGTAAGGCACCCTTATCTTTG
7307-LT2splice-F 5=-AGCAGCAGCTTGGTCCGGCTG
7209-LT2splice-R 5=-GCATATGCGAAGTAAGAGATTGT
LT1splice-F 5=-GGTCATCGCCAAGGTCACAT
LT1splice-R 5=-GCTTGGTCCGGCTGACTTAT
K14-ORF74splice-F 5=-TGGCCCAAACGGAGGATCCTAG
K14-ORF74splice-R 5=-AGTTTCATTCCAGGATTCATCATC
Enrichment of human lncRNA MALAT1
MALAT1 even 8 5=-CACTGCAAGGTCTCATACAC-TEG-Biotin
MALAT1 even 7 5=-CAACACTCAGCCTTTATCAC-TEG-Biotin
MALAT1 even 6 5=-CCACTGGTGAATTCAACTGG-TEG-Biotin
MALAT1 even 5 5=-CCTTAGGATAATAGCGCTTT-TEG-Biotin
MALAT1 even 4 5=-CTTGCTTTTAACAGGCTTCT-TEG-Biotin
MALAT1 even 3 5=-ATAGAGCTACTTAGCTGTGG-TEG-Biotin
MALAT1 even 2 5=-CCTACTGAAGAGCATTGGAG-TEG-Biotin
MALAT1 even 1 5=-TAGGGCTTCTCAAAACACCA-TEG-Biotin
Enrichment of KSHV lncRNA ALT
ALT even 8 5=-TATGGCAACTGCCAATAACC-TEG-Biotin
ALT even 7 5=-CCAGGAGATAATACACCAGA-TEG-Biotin
ALT even 6 5=-TCTCCAGAGTCTTCTCAAAG-TEG-Biotin
ALT even 5 5=-GGCACCCTTATCTTTGAAAT-TEG-Biotin
ALT even 4 5=-ACAGTGGGGGGTAAATTCTG-TEG-Biotin
ALT even 3 5=-AACGCGACACCAAAATGGGG-TEG-Biotin
ALT even 2 5=-ACAAGTAGTATAGGTGTTGT-TEG-Biotin
ALT even 1 5=-GTCACATCTGTGTACAAACC-TEG-Biotin
Enrichment of KSHV latency transcripts
Lat even 8 5=-TAAGTTATGGGCGACTGGTC-TEG-Biotin
Lat even 7 5=-CAAATGCAAGTGCGGAGCGG-TEG-Biotin
Lat even 6 5=-CGCGGCTCAATTTCAAGAAT-TEG-Biotin
Lat even 5 5=-CGTGAGGCTTCTGAGCTTAC-TEG-Biotin
Lat even 4 5=-TGCAGCGCTGATAATAGAGG-TEG-Biotin
Lat even 3 5=-CCGGCTTGTATATGTGAAGG-TEG-Biotin
Lat even 2 5=-CCTATAGTGTCCTTGCTTAA-TEG-Biotin
Lat even 1 5=-TACATACATTCTACGGACCA-TEG-Biotin
aTEG, triethyleneglycol spacer for more efficient binding to magnetic beads.
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produce three amplicons, two from spliced latency transcripts and one from unspliced
ALT lncRNA (Fig. 3). PCR amplification of cDNA from the Lat transcript isoform LT2
would result in a 392-bp amplicon, while relatively long amplicons would be produced
from either a Lat isoform with a short intron (LT1; 3,812 bp) or the ALT lncRNA (4,311
bp). To ensure that the LT2 primer pair amplifies only the 392-bp product spanning the
intron of isoform LT2, we varied the extension times during PCR on PEL cell DNA to
determine conditions under which the two long amplicons are not amplified. Thus, we
chose an extension time of 45 s, which underrepresents long products and yields a
single LT2-specific product from cDNA (Fig. 4A and B).
Additionally, two other primer pairs (LT1 or K14-ORF74, as listed in Table 2 and Fig.
3) were designed to amplify multiple products of different sizes in order to differentiate
between spliced or unspliced transcripts from either the same strand or opposite
strands. The first, the LT1 primer pair (Fig. 3), spans an intron from Lat isoform LT1 and
amplifies a product of 156 bp from that strand but a full-length amplicon of 655 bp
from the ALT lncRNA on the opposite strand. The second, the K14-ORF74 primer pair
(Fig. 3), spans an intron that is present in a subpopulation of the K14-ORF74 and ALT
lncRNA transcripts (19), and it amplifies either a 233-bp product from unspliced RNA or
an 85-bp spliced product. Finally, the ORF72 primer pair amplifies a single non-strand-
specific product that can originate from either the Lat transcripts or the ALT lncRNA. All
of these primer pairs gave the expected product using BCBL1 genomic DNA (Fig. 4B).
KSHV transcription expression is altered during lytic replication. Therefore, to de-
termine the best conditions for maximal expression of ALT, we interrogated latent and
lytic conditions. TREx BCBL1-RTA cells carry the potent inducible RTA/ORF50 expression
plasmid, and upon addition of doxycycline, the cells synchronously initiate lytic tran-
FIG 3 Schematic of the KSHV latency locus. The latency locus of KSHV was mapped with mRNAs in green and lncRNA ALT in purple. Dotted lines indicate two
sets of biotinylated ASOs (numbered as shown in Table 2), one designed to enrich ALT and one to enrich the latency (Lat) transcripts. Shaded blue regions and
lines below indicate potential amplicons. Polyadenylation (pA) signals are marked by black lines, and the right origin of lytic replication (ori-LytR) is shown by
a dark blue bar.
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scription (64). Our laboratory has extensively characterized transcription from the
latency locus in this cell line, and therefore we chose the time points of 12 and 24 h
postinduction to assess lytic changes in transcription.
To investigate the expression levels of transcripts on both strands of the latency
locus, we used oligo(dT) and random hexamers to reverse transcribe mRNA from either
latent or lytic cells and then assessed transcripts using the strand- or isoform-specific
primer pairs (Fig. 4A). Poly(A) RNA was quantified using the RNA HS assay on a Qubit
3.0 fluorometer, and the same mass of RNA was added to each RT reaction. Consistent
with our prior studies (68), two LANA transcripts, LT1 and LT2, were expressed at steady
levels during the latent and lytic stages, as seen with the Lat-specific LT2 primer pair
(Fig. 4A, lanes 10, 12, and 14) or with the 156-bp LT1-specific amplicon from the LT1
primer pair (Fig. 4A, lanes 18, 20, and 22). Given the massive changes in cellular
transcription during reactivation and the reproducibility of LT2 expression in this 24-h
period, we used LT2 as a control for transcript expression. The ALT-specific primer pair
(Fig. 4A, lane 4) and the LT1 primer pair (i.e., the 655-bp ALT-specific amplicon in Fig.
4A, lane 20) each amplified ALT, and we observed the highest expression of ALT relative
to LT2 at 12 h postlytic reactivation. We were able to detect both the spliced and
unspliced isoforms from the K14-ORF74 primer pair at all stages of the viral life cycle
(Fig. 4A, lanes 26, 28, and 30), which supports the results from the ALT-specific primer
FIG 4 KSHV lncRNA ALT is expressed during the early lytic stage, and a new splice isoform of a LANA transcript is found. (A) Expression of RNAs
during latency or 12 and 24 h postlytic reactivation, as detected by strand- or isoform-specific RT-PCR. The amplicons interrogated are listed above
each digital gel image and are illustrated in Fig. 3. (B) Oligonucleotide primers designed for RT-PCR and listed in Table 2 were first tested on BCBL1
genomic DNA. All but the LT2 primers yielded an amplified product from DNA. A short extension time during PCR was intentionally chosen to
avoid amplifying a full-length LT2 product from DNA to ensure these primers were specific for the spliced LT2 mRNA. (C) A new splice isoform
(LANA new, whose longer 5= UTR is highlighted in dark green) that contains the LANA CDS (yellow) and is expressed during the lytic stage
was identified with an earlier splice acceptor site (blue) than Lat transcript LT1 (5= UTR in light green). The amino acid sequences of three
small peptides encoded by uORFs that are only present in LANA new are shown in gray text below the RNA sequence, while that of LANA
is in black text.
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pair. No product was observed in the non-RT negative-control samples (Fig. 4A, lanes
3, 5, 7, 11, 13, 15, 19, 21, 23, 27, 29, and 31) or the nontemplate PCR control (NTC)
samples (Fig. 4A, lanes 8, 16, 24, and 32). The bands at or below 50 nucleotides
represent single-stranded primers and double-strand primer-dimers, which are only
visible due to the use of a high-sensitivity microfluidic device. It verifies that primer was
added in excess in all reactions.
Using the LT1 primer pair, we noticed an unexpected amplicon of 400 bp that is
absent from latent cells, appears at 12 h postreactivation, and is expressed at the
highest level at 24 h postreactivation (Fig. 4A, lanes 18, 20, and 22). We found the same
400-bp amplicon in JSC1 and BC1 cells, confirming this is not a cell line-specific
phenomenon. Further, we determined that this amplicon corresponds to a new splice
isoform of a LANA-containing transcript. This isoform has a canonical splice acceptor
site at genomic position 127888, which is upstream of the known acceptor site in
latency transcript LT1 at position 127640. This yields a corresponding intron that is
shorter than LT1, as shown in graphical form as LANA new (Fig. 3) and in a multiple-
sequence alignment (Fig. 4C) using the online tool MUSCLE, version 3.8 (69). The intron
of this new splice isoform lies entirely within the 5= untranslated region (UTR), as with
the intron of LT1, and therefore does not affect the LANA coding DNA sequence (CDS).
To improve the detection of the ALT lncRNA, we next sought to capture ALT prior
to reverse transcription. Because ALT was expressed at its highest level at 12 h
postreactivation (Fig. 4A, lanes 4 and 20), this time point was used for all subsequent
experiments. To ensure the most complete lytic reactivation from doxycycline-
inducible TREx BCBL1-RTA cells, we induced with doxycycline and added the
histone deacetylase inhibitor valproic acid (VPA). Unlike other inducers, such as
n-butyrate, 12-O-tetradecanoylphorbol-13-acetate (TPA), or vorinostat/suberanilohy-
droxamic acid (SAHA), VPA exhibits no toxicity in PEL even after prolonged incubation.
We also added foscarnet/phosphonoformate (PFA) to abolish KSHV DNA replication,
nuclear reorganization due to the formation of replication compartments, and prema-
ture cell lysis. This increases the chances of detecting authentic, transcriptionally
regulated lytic lncRNAs, rather than fragmented, abortive transcription across replicat-
ing episomes. To establish strand specificity, we sought to enrich ALT and the Lat
transcripts in separate ASO pools. We designed these pools of biotinylated ASOs
clustered near the 3= end of both sets of transcripts, avoiding repetitive regions (Fig. 3,
dotted black lines, with numbering as shown in Table 2). For ALT, ASOs were distributed
evenly throughout the predicted length of the lncRNA, while ASOs for Lat transcripts
were grouped within a common region at the 3= end to maximize the capture of all Lat
transcripts.
To assess the enrichment of ALT and Lat transcripts, we performed RT-PCR on input
or captured RNA using the strand- or isoform-specific amplicons within the latency
locus (Fig. 3, blue shading) and a negative-control amplicon within the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene. No amplification was observed in the
negative-control samples incubated without RT (Fig. 5). Capture ASOs from both
strands were effective, as the ORF72 primer pair, whose amplicon is not strand specific,
equally amplified a single product in ALT- and Lat-captured RNA at levels similar to
those of input RNA (Fig. 5A). The topography of the KSHV genome is highly repetitive
and highly GC rich, leaving few targets for optimal design of ASOs. This, coupled with
the low temperature at which ASO binding occurs, means that the expected outcome
for this assay is enrichment, not isolation, of our target. Thus, we observe that some
GAPDH is amplified in the captured RNA from each ASO pool (Fig. 5B), but at a much
smaller amount than the intended target RNAs (e.g., ORF72) (Fig. 5A).
ALT was enriched in ALT-captured RNA compared to Lat-captured RNA (Fig. 5C, E,
and F, left versus right side), as seen with either the ALT-specific primer pair (Fig. 5C),
the 655-bp ALT-specific amplicon from the LT1 primer pair (Fig. 5E), or both K14-ORF74
amplicons (Fig. 5F). Conversely, the Lat transcripts were only amplified efficiently in
Lat-captured but not ALT-captured RNA relative to input RNA (Fig. 5D and E, right
versus left side), as seen with the Lat-specific LT2 primer pair (Fig. 5D) and the 156-bp
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Lat-specific amplicon from the LT1 primer pair (Fig. 5E). These data establish the
presence of KSHV ALT by a direct, strand-selective approach independent of potential
interpretation biases inherent to short-read sequencing and current heuristic, short-
read mapping algorithms.
Identification of ALT 5= and 3= ends using RNA-seq. Having established the
specificity of our enrichment method, we sought to define the ends of captured lncRNA
by RNA-seq analysis. To this end, we created strand-specific RNA-seq libraries from TREx
BCBL1-RTA cells 12 h postreactivation with or without ASO enrichment. We next
aligned all sequence reads from ALT-enriched RNA to the KSHV strain JSC1 genome
(GenBank accession number GQ994935.1). To identify 3= ends and transcription termi-
nation sequences (TTS), we searched for genomic regions where an abundance of
sequence reads contain a poly(A) tract that does not match the reference genome and
identified the initial nonmatching adenine. We then determined the percentage of all
reads in that genome position that contain adenine or any other nucleotide on either
strand. As expected (11, 70), all poly(A)-containing reads in the latency locus data set
aligned to known TTS of the Lat transcript, one at JSC1 genomic position 122510 (30%
of all reads at that position), which is 3= to ORF71, and one at position 117247 (82% of
reads), which is 3= to Kaposin/K12 (Fig. 6B).
FIG 5 ALT is enriched in a strand-specific manner. Strand- and isoform-specific RT-PCR was performed on
ALT-captured, Lat-captured, or input RNA using the non-strand-specific primer pair ORF72 (A), negative-
control GAPDH (B), the ALT-specific primer pair (C), the Lat-specific LT2 primer pair (D), or the isoform-
specific LT1 (E) and K14-ORF74 (F) primer pairs, whose amplicons are illustrated in Fig. 3. ALT was
amplified at 12 h postlytic reactivation in ALT-captured but not Lat-captured RNA, while latency
transcripts were only amplified in Lat-captured RNA.
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We identified a TTS downstream of the common ALT and K14-ORF74 polyadenyl-
ation (pA) signal. For this TTS shared by the coterminal ALT lncRNA and K14-ORF74
transcripts, 94% of all reads contain 5 adenine residues starting at position 130873
(Fig. 6A), while 6% of reads span this position in either direction. These results were
obtained from RNA-seq analysis of ALT-enriched RNA, but similar percentages were
observed at the same position in libraries from non-ASO-enriched RNA (all raw reads
are available in the NCBI Sequence Read Archive under accession code SRP082699). As
the two genome-encoded adenine residues upstream of position 130873 interfere with
determining the exact start of this poly(A) tract, this result is consistent with the
published TTS at positions corresponding to 130870 to 130872 in the JSC1 genome (13,
19, 21, 59, 60).
To examine the TSS of the ALT lncRNA, we mapped a continuous stretch of reads in
the same strand orientation as the 5= region of the ALT lncRNA (Fig. 6B). These reads
covered the first 1,500 nucleotides of ALT but were not present in the region
upstream of the published ALT TSS. Reads were clustered near the two reported 5= ends
of the ALT lncRNA, including the long predominant isoform starting at a position
corresponding to 120739 in the JSC1 genome and the short isoform at 121012 (19). We
also examined other properties of the ALT lncRNA. To explore the potential splicing of
ALT, we used two different tools (71, 72) that predicted 200 potential splice donor
and splice acceptor sites within the 10 kb of this lncRNA. Of note, each of these tools
FIG 6 Identification of ALT 5= and 3= ends using RNA-seq analysis. (A) Strand-specific RNA-seq was performed on ALT-captured RNA from TREx
BCBL1-RTA cells at 12 h postlytic reactivation, and reads were aligned to the KSHV strain JSC1 genome using BBMap. Nearly all reads downstream
of the common ALT and K14-ORF74 pA signal (orange) contain 5 adenine residues starting at position 130873 (GQ994935.1), consistent with
published reports, while the remainder span this position in either direction. (B) Reads in the latency locus from the top (blue) and bottom
(orange) strands were visualized using Genomics Workbench. Reads align near the published 5= end of the ALT lncRNA (19).
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confirmed the known splice donor/acceptor pair at JSC1 genomic positions 129545 and
129694, respectively, which represents the only known intron shared by the K14-ORF74
and ALT lncRNA transcripts (19); however, we found no evidence in our RNA-seq data
of intra-ALT splice sites.
Although the ends of ALT are clearly defined in our data, we note that there are a
few interior areas that have poor read coverage, particularly in repetitive regions. Lack
of coverage in the repetitive region within ALT is due to an inherent inability of the
BBMerge algorithm to extend reads through repeats. Lack of coverage in other areas is
likely due to reduced efficiency of cDNA initiation during reverse transcription or
sequence-dependent reduced efficacy of sequencing chemistry used in the Illumina
machine. In sum, our experiments confirmed the existence of the ALT lncRNA in KSHV
by direct, strand-specific, sequencing-independent means (RT-PCR), uncovered a novel
splice site in the 5= UTR of LANA, and verified the termination and start site of the ALT
lncRNA.
DISCUSSION
This work firmly establishes ALT as a bona fide KSHV lncRNA and thus provides the
foundation and justification for further functional and genetic studies. The KSHV PAN
lncRNA is so abundant that it can be identified by Northern blot analyses (22, 25). All other
KSHV lncRNAs are either significantly less abundant or are inconsistently expressed and
have not been verified by multiple, independent experimental approaches. With this work,
ALT now has attained a status of significance and reproducibility similar to that of PAN RNA,
and we provide a high-sensitivity, high-specificity, low-cost RT-PCR-based assay to distin-
guish ALT and LANA pri-miRNA expression patterns in KSHV.
The technical goal of this work was to validate a relatively fast and inexpensive
method to enrich strand-specific RNAs that uses as few tiling oligonucleotides as
possible. Other methods of enriching RNA require either a large pool of overlapping or
closely spaced oligonucleotides tiled equally over the entire length of the target RNA
or an oligonucleotide empirically determined to bind effectively (62, 73, 74). As several
potential lncRNAs in KSHV are5 kb (Table 1), adapting a tiled oligonucleotide method
to enrich one or more of these viral lncRNAs can become prohibitively expensive.
We identified a new splice isoform (LANA new) originating from the latency cluster
that is only expressed during lytic replication (Fig. 4A and C). Although most transcripts
from the latency locus have high basal expression during latency and are not inducible
by the lytic cycle regulator RTA or by chemical inducers of reactivation (11, 30, 66, 75),
at least one other LANA-containing transcript, labeled LANA LytT in Fig. 3, is also
inducible during the lytic stage (76). However, the LANA LytT transcript is controlled by
a separate RTA-inducible promoter that is downstream of the constitutive latent
promoter (76) and is located entirely within the intron of the LANA new isoform,
suggesting that the LANA new transcript is controlled by yet another unidentified
inducible lytic promoter. It is intriguing to speculate what effect alternative splicing of
the LANA new isoform would have on translation of its CDS. Although the shorter
intron of the LANA new splice isoform does not affect the LANA CDS, it contains a
longer 5= UTR than that of Lat transcript LT1 (Fig. 4C). The expanded 5= UTR of this new
LANA transcript isoform contains three additional upstream ORFs (uORFs), which are start
and stop codons upstream of the main coding sequence. As uORFs generally decrease
synthesis of downstream proteins (77), these additional uORFs in the LANA new isoform
(Fig. 4C) can potentially lower the translation of the LANA protein in lytic cells relative to
latent cells while allowing for continued expression of the KSHV miRNA cluster.
The complex and interconnected nature of the KSHV transcriptome bestows key
characteristics for regulating gene expression that are still not fully understood. More
than half of all KSHV ORFs are carried on polycistronic transcripts, 25% of all ORFs are
carried by spliced mRNAs, and a few transcripts share promoters and/or pA signals (13,
21, 59, 60, 78, 79). The ALT lncRNA is coterminal with the bicistronic mRNA K14-ORF74
and includes the K14 and ORF74 CDS, but it is expected that K14 and ORF74 proteins
are not translated from ALT, as these ORFs are 8 kb downstream of the ALT TSS.
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However, as microRNAs regulate gene expression by targeting 3= UTRs for downregu-
lation or degradation (79), the 3= UTR common to ALT and the K14-ORF74 mRNA is
likely subject to similar microRNA regulation. Some human miRNAs can downregulate
the 3= UTRs for K14 and ORF74 in latent PEL cells (60), and it is possible that these
microRNAs have the same effect on ALT. It is speculated that grouping specific genes
into bi- or polycistronic transcripts allows KSHV to maximize its coding capacity and
level of gene regulation (78, 79). For example, splicing of one bicistronic mRNA that
disrupts a large portion of the upstream ORF allows expression of the downstream
protein (80). However, it is unknown what effect the lengthy 5= UTR of ALT has upon
its downstream CDSs K14 and ORF74, and it is possible that K14 and ORF74 proteins are
exclusively translated from the two splice isoforms of K14-ORF74 bicistronic transcripts.
The potential interactions and coregulatory functions of the ALT lncRNA with nearby or
overlapping transcripts on both strands are numerous and poorly understood.
Finally, we provide a resource to the KSHV community (KSHV 2.1) by critically
evaluating and integrating a series of mapping studies with an emphasis on viral
ncRNAs. Just as more in-depth studies of the KSHV miRNAs (81–84) uncovered and
highlighted the importance of structural variations (i.e., single-nucleotide variants with
functional consequences, alternate strand incorporation, and alternate 5= or 3= end
processing), this in-depth study of the KSHV lncRNAs affirms their existence and hints
at their possible roles in viral gene expression, genome replication, and pathogenesis.
MATERIALS AND METHODS
Cell culture and reagents. The KSHV-infected primary effusion lymphoma (PEL) cell line TREx
BCBL1-RTA (64) was cultured in RPMI 1640 medium (Gibco), incubated at 37°C in 5% CO2, and
supplemented with 10% tetracycline-free fetal bovine serum (Omega Scientific), L-glutamine (2 mM;
Gibco), 100 g/ml streptomycin sulfate, and 100 U/ml penicillin G (Corning). Lytic reactivation of KSHV was
induced with doxycycline (1 g/ml) and valproic acid (1 mM) in the presence of foscarnet (phospho-
noformate; 100 M).
RNA isolation. RNA was isolated from TREx BCBL1-RTA, JSC1, and BC1 cells. Doxycycline, valproic
acid, and foscarnet were added when cultures reached the desired population of 10 million cells for
total RNA or 100 million cells for poly(A) RNA. The culture was either harvested immediately or growth
was continued for 12 or 24 h postinduction. Cells were pelleted by centrifugation at 300  g for 5 min,
and supernatants were removed. Cell pellets were resuspended in TRI Reagent (Molecular Research
Center) and lysed according to the manufacturer’s protocol, except an additional extraction was
performed using acidic phenol-chloroform-isoamyl alcohol (125:24:1; Fisher). RNA pellets were dissolved
in nuclease-free water and treated with 0.12 U/l of TURBO DNase using a TURBO DNA-free kit (Life
Technologies) according to the manufacturer’s protocol. Removal of DNA was assessed by RT-PCR
(described below), and RNA quality was determined using an RNA 6000 NanoChip on a Bioanalyzer
instrument (Agilent). RNA was quantified using the RNA HS assay on a Qubit 3.0 fluorometer (Invitrogen).
Poly(A) RNA was selected using Oligotex mRNA kits (Qiagen) according to the manufacturer’s protocol,
except that bead-bound RNA was first eluted twice with the same aliquot of nuclease-free water heated
to 70°C and then eluted with an additional four aliquots of heated water. RNA in each eluted sample was
quantified using Qubit 3.0. Poly(A) RNA was used to assess the expression of ALT and the Lat transcripts
by RT-PCR (Fig. 4A) and to generate RNA-seq libraries from one set of biological replicates, while total
RNA was used in all other RT-PCR or RNA-seq experiments.
Enrichment of specific RNAs by biotinylated ASOs. Oligonucleotides antisense to the RNAs of
interest were designed using the Stellaris online tool ChIRP (chromatin isolation by RNA purification)
Probe Designer, based on work from the Chang laboratory (62, 63). ASOs were designed to bind to
nonrepetitive regions of RNA, and biotin was added to the 3= end along with a triethyleneglycol spacer
to allow for more efficient binding to magnetic beads (Eurofins). ASO-mediated enrichment of poly(A)
RNA was used to generate a single RNA-seq library (ALT03) (Fig. 6), while ASO-enriched total RNA was
used in other RT-PCR experiments (Fig. 2B and 5). For enrichment,2.0 g poly(A) RNA from70 million
cells or 20.0 g total RNA from 2 million cells was incubated with 100 pmol of pooled biotinylated
ASOs in ChIRP hybridization buffer (750 mM NaCl, 1% SDS, 50 mM Tris-HCl, pH 7.0, 1 mM EDTA, 15%
formamide) (63) and RiboLock RNase inhibitor (Thermo Fisher Scientific) at 37°C for 2 h. ASO-bound RNA
was then isolated by adding 100 pmol streptavidin-coupled magnetic beads in binding solution from a
Dynabeads kilobaseBINDER kit (Invitrogen) and incubating on a rotator at room temperature for 2 h.
Beads were washed and RNA was eluted in 10 mM Tris-HCl, pH 7.0, heated at 85°C for 2 min. The
concentration of enriched RNA was determined using a Qubit 3.0 fluorometer (Invitrogen) as mentioned
in “RNA isolation” above.
Assessment of RNA expression or ASO enrichment by RT-PCR. Poly(A) RNA was used to assess the
expression of ALT and Lat transcripts by RT-PCR (Fig. 4A), and ASO-enriched poly(A) RNA was used to
generate the RNA-seq library ALT03 (Fig. 6). ASO-enriched or non-ASO-enriched (input) total RNA was
used in RT-PCR experiments (Fig. 2B and 5). Total RNA, poly(A) RNA, or ASO-enriched RNA was reverse
transcribed using ThermoScript reverse transcriptase (Invitrogen) with the following slight modifications
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to the supplier’s protocol. The annealing step was performed with 90 to 140 ng of RNA and either with
oligo(dT)20 or a mix of oligo(dT)20 and random hexamer primers at 75°C for 5 min. Reverse transcription
was performed at 25°C for 10 min and 55°C for 15 min, and then heat inactivation was performed at 85°C
for 5 min. The resulting cDNA was amplified using GoTaq Green master mix (Promega) and the pairs of
oligonucleotide primers listed in Table 2. PCR primers were first tested on genomic DNA isolated from
BCBL1 cells (Fig. 4B). For RT-PCR, cycling conditions included an initial denaturation step of 95°C for 30
s, amplification for 35 cycles (denaturation at 95°C for 20 s, annealing at 56°C for 20 s, and extension at
72°C for 30 s), and a final extension at 72°C for 1 min. Cycling conditions for genomic DNA were the same,
except the extension time was 45 s. The reactions were run by capillary electrophoresis on a Caliper
LabChip GX microfluidic instrument (PerkinElmer).
Preparation of RNA for high-throughput sequencing. Strand-specific RNA-seq libraries were
made using total RNA, poly(A) RNA, or ASO-enriched RNA (22 to 85 ng) from PEL cells 12 or 24 h
postreactivation and the Ovation Universal RNA-seq system (NuGEN) with the following modifica-
tions to the supplier’s protocol. cDNA was fragmented to an approximate size range of 200 to 500
bp using a TruSeq protocol (i.e., parameters included 5% acoustic factor, 175-W peak incident power,
and 200 cycles per burst) with a modified treatment time of 40 s on a Covaris E220 focused
ultrasonicator instrument. Human rRNAs were depleted using the provided NuGEN insert-dependent
adapter cleavage primers. Libraries were amplified for 20 to 21 cycles. Final cDNA libraries were
quantified using the dsDNA HS assay on a Qubit 3.0 fluorometer (Invitrogen), while the size
distribution was determined using a high-sensitivity DNA chip on a Bioanalyzer instrument (Agilent).
All libraries were paired-end sequenced using an Illumina HiSeq 2500 instrument for 50-bp or
100-bp read lengths.
RNA-seq data analysis. Sequence reads were trimmed using bbduk.sh (ktrim  r, k  23, hdist 
1) from the BBMap suite v.36.20 (https://sourceforge.net/projects/bbmap/) and the adapters.fa file
included in the BBMap software that contains sequences for commonly used adapters from next-
generation sequencing library preparation. Since the 50-bp reads used in this study do not overlap, we
used a feature in the BBMerge program (included in the BBMap suite) that makes use of a tadpole (a read
assembling program, also included in the BBMap suite). BBMerge tries to extend the 3= end of each read
via assembly using kmer frequencies. BBMerge was run on input read files (R1/R2) with these parameters
(k  31, extend2  200) to allow extension of reads up to 250 bp (Brian Bushnell, personal communication,
and unpublished BBMerge manuscript). Reads (adapter-trimmed original or merged using BBMerge) were
mapped with BBMap (with maxindel 4000, intronlen 10, ambig random, qin 33, sam 1.3; the rest
of the parameters were default) to the KSHV strain JSC1 genome (GQ994935). BBMap is able to generate
alignment results directly as BAM files when SAMtools (v.1.3.1) software is available on the server. We
obtained between 3 and 13 million sequence reads that aligned to the JSC1 genome.
We identified the 3= ends of RNA transcripts in the latency locus of KSHV by using Integrative
Genomics Viewer (IGV) v.2.3.79 (85). We first found genomic regions for which the majority of sequence
reads contain 2 adenine residues that do not match the reference genome and form a poly(A) tract
of 5 nucleotides, and we visually inspected each genomic position in that region to identify the initial
nonmatching adenine. For that particular genomic position and its surrounding positions, we then used
bam-readcount v.0.7.4 (https://github.com/genome/bam-readcount) to report the number and percent-
age of reads that contain each nucleotide base on either strand. We visualized 5= ends by using Genomics
Workbench software v.9.0.1 (CLC bio) to identify collections of sequence reads all in the same strand
orientation without any upstream reads.
Accession number(s). The sequence data have been deposited in the NCBI Sequence Read Archive
under accession code SRP082699, and the annotated .gff file is available at https://www.med.unc.edu/
orfeome/downloads/annotated-target-genomes.
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